Joseph Baroldi Sells 4,006 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Joseph Baroldi sold 4,006 shares of Ionis Pharmaceuticals stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $41.60, for a total transaction of $166,649.60. Following the completion of the sale, the executive vice president now directly owns 19,631 shares of the company’s stock, valued at approximately $816,649.60. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Ionis Pharmaceuticals Stock Performance

NASDAQ:IONS opened at $40.81 on Friday. The firm’s 50-day moving average is $44.07 and its 200-day moving average is $47.30. Ionis Pharmaceuticals, Inc. has a 52-week low of $34.32 and a 52-week high of $54.44. The company has a debt-to-equity ratio of 3.18, a quick ratio of 5.83 and a current ratio of 5.90. The company has a market cap of $5.95 billion, a price-to-earnings ratio of -15.94 and a beta of 0.39.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings data on Wednesday, February 21st. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.72. The company had revenue of $325.00 million for the quarter, compared to the consensus estimate of $176.01 million. Ionis Pharmaceuticals had a negative net margin of 46.32% and a negative return on equity of 90.29%. The business’s revenue was up 113.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.37) EPS. Equities research analysts anticipate that Ionis Pharmaceuticals, Inc. will post -4 earnings per share for the current year.

Analyst Upgrades and Downgrades

IONS has been the subject of several analyst reports. JPMorgan Chase & Co. lifted their price objective on shares of Ionis Pharmaceuticals from $52.00 to $55.00 and gave the company a “neutral” rating in a research note on Thursday, February 1st. Oppenheimer lifted their price objective on shares of Ionis Pharmaceuticals from $72.00 to $75.00 and gave the company an “outperform” rating in a research note on Tuesday, April 9th. Piper Sandler boosted their target price on shares of Ionis Pharmaceuticals from $62.00 to $63.00 and gave the stock an “overweight” rating in a research report on Thursday, February 22nd. William Blair reissued an “outperform” rating on shares of Ionis Pharmaceuticals in a research report on Tuesday, April 9th. Finally, Bank of America raised shares of Ionis Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $52.00 to $62.00 in a research report on Tuesday, January 2nd. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Ionis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $56.08.

Institutional Trading of Ionis Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. HealthInvest Partners AB bought a new stake in Ionis Pharmaceuticals in the fourth quarter valued at about $1,226,000. Charles Schwab Investment Management Inc. boosted its position in Ionis Pharmaceuticals by 3.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,242,307 shares of the company’s stock valued at $56,351,000 after buying an additional 43,087 shares in the last quarter. Trexquant Investment LP boosted its position in Ionis Pharmaceuticals by 75.2% in the third quarter. Trexquant Investment LP now owns 183,349 shares of the company’s stock valued at $8,317,000 after buying an additional 78,724 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in Ionis Pharmaceuticals in the fourth quarter valued at about $9,329,000. Finally, SG Americas Securities LLC boosted its position in Ionis Pharmaceuticals by 113.3% in the third quarter. SG Americas Securities LLC now owns 41,571 shares of the company’s stock valued at $1,886,000 after buying an additional 22,078 shares in the last quarter. Institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.